SciFi Futures
← Capabilities
Biotech & Medicine/Integrated system

Biofabrication of vascularized human organs

Building a human-sized, perfusable, functioning organ - kidney, liver or heart - from a patient's own or banked cells.

State of the art

ARPA-H PRINT awarded teams in January 2026 (Wake Forest vascularized renal tissue, Wyss clinical-scale liver tissue, among others) to attempt what the agency states has not been done - printing a human-sized functional organ.

What’s blocking it
  • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
  • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
  • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
  • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route

Who’s working on it

  • Awarded five teams up to 176.8 million dollars over five years in January 2026 to attempt what the agency says has not been done, a human-sized functional printed organ

  • Anthony AtalaResearcher
    Wake Forest Institute for Regenerative Medicine

    Principal investigator of the award of up to 24.8 million dollars announced January 2026 to produce clinical-grade vascularised renal tissue

  • Wyss InstituteAcademic lab

    PRINT awardee engineering universal clinical-scale liver tissue from adult stem cells as an implantable therapy

  • Carnegie Mellon UniversityAcademic lab

    PRINT awardee building a cost-effective immune-silent bioprinted liver for acute liver failure, targeting first-in-human within five years

  • UT Southwestern Medical CenterAcademic lab

    PRINT awardee developing a transplant-ready liver with reconnected blood vessels and a bile duct system, the mechanical-integration problem nobody has solved

  • United TherapeuticsCompany

    The only established company industrialising manufactured transplantable organs at scale, through gene-edited pigs and dedicated organ manufacturing facilities

  • PrintBioStartup

    Commercial partner in the federal kidney bioprinting programme, working on print-and-perfuse hardware rather than therapeutics

What to invest in

KindInvestmentScale
engineeringOrgan-scale print-and-perfuse platforms with integrated bioreactor maturation, measured against transplant function endpoints in large animals$$$ $100M – $1B
researchMaturation protocols (flow, electrical, metabolic conditioning) that move printed tissue from fetal to adult function$$$ $100M – $1B

Sci-fi concepts in reach

Autodoc medical poddirectEngineered organ-donor animalsdirectResurrection of extinct speciesindirectWhole-body rejuvenation treatmentdirectOn-demand replacement organsdirectAI cybrid (AI persona in a grown human body)indirectIndustrial ectogenesis (hatcheries)indirectNexus-6 androids (replicants)indirectCruciform resurrection parasitedirectResleeving (transferring a mind into a new body)indirect

Sources